Treatment of rheumatoid arthritis: state of the art 2009.
about
miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilizationDevelopment of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacyOfatumumab for rheumatoid arthritisSKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophageA metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritisBiologics registers in RA: methodological aspects, current role and future applications.Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response.Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Psychophysiological responses to stress after stress management training in patients with rheumatoid arthritisMeta-analysis of crowdsourced data compendia suggests pan-disease transcriptional signatures of autoimmunity.Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participantsNovel method of monitoring trace cytokines and activated STAT molecules in the paws of arthritic mice using multiplex bead technology.Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promiseDiscovery of serum protein biomarkers in rheumatoid arthritis using MALDI-TOF-MS combined with magnetic beads.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Accelerating translational research by clinically driven development of an informatics platform--a case study.Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression.JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis.Eupatilin ameliorates collagen induced arthritis.The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritisTreatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.Association of MASP-2 levels and MASP2 gene polymorphisms with rheumatoid arthritis in patients and their relatives.The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in ratsCharacterization of a novel and spontaneous mouse model of inflammatory arthritis.Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patientsPregnancy amelioration of arthritis in SKG mice corresponds with alterations in serum amyloid A3 levelsThe Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse ModelPharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.The application of optical coherence tomography in musculoskeletal disease.Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.Transport of anti-IL-6 antigen binding fragments into cartilage and the effects of injury.Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis.
P2860
Q21135455-45F66E16-FBA2-40FA-933C-2C6CD09ACFB4Q22000845-727D3D59-EAA2-4F55-AF16-526E5B7EE46DQ24202719-14F9449E-2029-4166-9EC1-F997140A333CQ28486238-BE4D2D0C-159B-412C-BBF9-7791FB9E6796Q28534911-A17A755A-75C1-4301-AD70-8919C6127220Q30234303-7634849D-D79A-406A-B88E-527191AA1C23Q30495832-41567752-FFFA-4ECB-A55A-9E261716FD73Q30540705-0F1D9924-A804-4050-9D67-C17102C86A91Q30560471-6B4577B0-3CAB-42F4-9414-3B7C5EA5C17EQ30891297-0D31A0AF-CD6E-4A20-BA1A-1F1CAD030452Q31043299-9717884C-C41F-4847-B0D6-1C4F252455C0Q33589316-249EC7E5-87BD-4CBA-991C-087A6A6ED2E9Q33653945-460017A3-BC03-4B7F-A58A-945D08929DA9Q33745759-6860C709-0E55-40FB-9D44-96761AED5A77Q33923444-1B815651-FDA9-4E0A-94C2-89A703729BFDQ34020523-4A105826-1B08-4106-BC19-D202F5CA5574Q34083054-9C61EE90-D428-46F1-821E-C3BA0804AFD8Q34155502-ECAC4480-95CF-4733-88E0-44787E912A9EQ34320329-8FCCA2AB-A188-4D07-8FA8-B6D4234C82D7Q34346251-917B74A8-7BAF-4AEC-B7A0-B23545EDD5C1Q34354935-44CC5AAE-A91C-4171-B382-B5C9490F0A82Q34361748-1FC95E8C-DC35-493F-A1F6-2B2A74E1FB20Q34625994-7400AE93-2915-4266-BF8E-6A8D1165A2B4Q34828241-D38D59F1-6144-46F2-B630-BF37F581ACB4Q35019433-3736FD5F-FDC1-4EC4-99C2-61B651619BD2Q35089292-8F86A412-BB86-4D94-9DB6-175EA27F7D01Q35092895-B23359CE-5E94-458C-BF51-81DC74DF1C74Q35092982-1B915B9F-10D8-4D22-B8A7-AA5C7CC86BDAQ35121560-30C1AE0A-1F8B-4F9D-9F68-11401C8AF10EQ35216463-C4D488A2-A865-4EB1-A810-8F55950E95BEQ35617627-3EDCF8BC-21C2-4F07-BE38-4B1BFCFE9064Q35620325-4306C34E-BF9E-4A13-90A5-E6E72126917AQ36338397-833EF707-DFBF-40CD-BAE9-9802A72F89FEQ36403152-C1A5F0C8-7518-42A7-8322-D293156E724EQ36441438-C7302727-DCE7-4DD8-B92D-BEFF6962FA07Q36599350-F8F04F4B-E3C2-486A-A96F-5E2AF1087411Q36649448-47D1BDF6-F4AB-4AD3-917E-6F0199042653Q36681123-5CFF6F2A-CEF8-476A-BBF3-8B2B4FBF2DE1Q36706945-6F05C2F7-68B3-4D15-BE70-75AD86C62CCDQ36975464-86C37F21-FA8B-477F-84B4-382674729371
P2860
Treatment of rheumatoid arthritis: state of the art 2009.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of rheumatoid arthritis: state of the art 2009.
@en
Treatment of rheumatoid arthritis: state of the art 2009.
@nl
type
label
Treatment of rheumatoid arthritis: state of the art 2009.
@en
Treatment of rheumatoid arthritis: state of the art 2009.
@nl
prefLabel
Treatment of rheumatoid arthritis: state of the art 2009.
@en
Treatment of rheumatoid arthritis: state of the art 2009.
@nl
P356
P1476
Treatment of rheumatoid arthritis: state of the art 2009.
@en
P2888
P304
P356
10.1038/NRRHEUM.2009.182
P407
P577
2009-10-01T00:00:00Z